HistoryofThisDivisionResearchObjectivesMembersIn-house Members Faculty of Pharmaceutical Sciences Takeshi Wada (Organic chemistry) Makiya Nishikawa (Drug delivery system) Takehisa Hanawa (Medicinal formulation) Yoshikazu Higami (Molecular pathology and metabolic diseases) Kazunori Akimoto (Molecular pathology) Chikamasa Yamashita (Physical pharmacy) Yosuke Harada (Immunology) Faculty of Science Satoru Miyazaki (Bioinformatics) Hidetaka Torigoe (Biophysical chemistry) Hidenori Otsuka (Polymer chemistry) Faculty of Advanced Engineering Chiharu Nishiyama (Immunology, allergy and molecular biology) Suguru Yoshida (Organic synthesis)CurrentSituationofNucleicAcidDrugsandOurResearchTopicsThis division was established by the cross-departmental team of in-house researchers working on the nucleic acid or other related research fields. By succession of networks and joint researches created through the activity of the TR center, we aim to develop innovative nucleic acid drugs from TUS.Figure 2DirectorProfessor,Department of Pharmaceutical SciencesDoctor of ScienceFuture Development GoalsOur goal is to make a breakthrough in the field of nucleic acid drugs through the Established: April, 2019ObjectivesWe aim to create nucleic acid drugs to treat unprecedented target diseases through the synthesis of novel chemically-modified nucleic acids and the establishment of DDS and formulation methods.collaboration of researchers within the university.Figure 1 Oligonucleotides as therapeutic agents twada@rs.tus.ac.jp19Developmental ImmunologyTakeshiWadaOrganic ChemistryMakiyaNishikawaDrug Delivery SystemSciencesSatoruMiyazakiKazunori AkimotoChikamasa YamashitaTakehisaHanawaMedicinal FormulationYosuke HaradaRyo GoitsukaFaculty of Advanced EngineeringMasayuki SakuraiSuguru YoshidaOrganic synthesisSciencesBioinformaticsOncologyPhysical pharmacyImmunologyRNA EditingImmunology Faculty of PharmaceuticalYoshikazu HigamiMetabolic Diseases Research Institute of Biomedical TheDivisionofNucleicAcidDrugDevelopmentFaculty ofScienceHidetaka TorigoeBiophysical ChemistryHedenoriOtsukaPolymer ChemistryChiharu Nishiyama The TR (Translational Research) center, which was the former organization of this division and lasted until 2018, got notable results in the field of nucleic acid drug. Also, nucleic acid-based drugs have recently attracted much attention as a next generation type drug. There are a plenty of researchers who work on nucleic acids at TUS, and the most of them took part the activity of TR center. Then, “round-table conference on nucleic acid drugs and DDS” was established in 2017 (representative: Prof. Makiya Nishikawa), and we have active discussions on nucleic acid drugs. Under these circumstances, the Division of Nucleic Acid Drug Development was established as a subsequent organization of TR center in April 2019. The development of nucleic acid drugs requires a knowledge from wide range of research field. There are many prominent researchers who work on nucleic acid or related research at TUS, thus innovative and unique results are highly anticipated through their collaborations. In this division, one of our mission is the development of novel nucleic acid derivatives which overwhelm conventional ones in the viewpoint of efficacy, stability and safety. Also, we aim at establishing the cationic molecules and formulation technology which stabilize and improve pharmacokinetics of nucleic acid drugs. We chose immune system, metabolic system related diseases and cancer as targets. As just described, the development of original nucleic acid drugs targeting unique diseases are highly expected by gathering of in-house competent researchers in this division. Research Institute of Biomedical Sciences Ryo Goitsuka (Developmental immunology) Masayuki Sakurai (RNA editing) Nucleic acid-based drugs are anticipated to be an epoch-making remedy for the treatment of intractable hereditary diseases. The global market size of nucleic acid-based drugs is predicted to expand to 19 billion dollars in 2030 from 2 billion dollars in 2018, according to the estimation of Seed Planning Inc., a marketing research and consulting enterprise. Although much efforts have been devoted to the research of nucleic acid-based drugs, only 17 drugs have been approved so far. There are a lot of challenges to overcome for the development of potent nucleic acid drugs, and a break-through is required for the further progress of this area. To address this issue, we are dealing with following topics;1. Development of an efficient method to synthesize boranophosphate oligonucleotides which is anticipated as an alternative candidate of phosphorothioate2. Establishment of a scalable synthetic method of artificial cationic oligosaccharides and peptides that bind to and stabilize nucleic acids.3. Construction of a highly target selective drug delivery system through the elucidation of interaction between nano-structured nucleic acid and cells4. Development of antisense drugs that target such as wound and bladder cancer remedy5. Development of a novel formulation method of nucleic acid drug6. Research on the control of aging, aging related diseases and metabolic abnormalities by nucleic acid drugs7. Development of nucleic acid drugs which regulate autoimmune response and rejection reaction during an organ transplantation8. Development of effective breast cancer drugs using novel artificial cationic molecules and siRNAs9. Establishment of investigation technology via bioinformatics and AI to determine the sequence of a mRNA that codes disease-related proteinDevelopment of nucleic acid-based drugs that are expected to be a next-generation drugTakeshi WadaDivision of Nucleic Acid Drug Development
元のページ ../index.html#19